Emily MenendezmCSPC | July 17, 2024
Darolutamide plus ADT provided a clinically meaningful increase in rPFS compared with placebo plus ADT.
Read More
Benjamin H. LowentrittASCO 2024 | June 10, 2024
Dr. Lowentritt sheds light on a real-world comparison of PSA response in patients with mCSPC treated with apalutamide.
Brandon TwyfordmCSPC | June 3, 2024
Intensified androgen blockade improves PSA progression-free survival in prostate cancer without affecting quality of life.
Katy MarshallmCSPC | June 3, 2024
The ArteraAI MMAI prognostic biomarker performs risk stratification of patients with localized prostate cancer.
Katy MarshallmCSPC | May 17, 2024
Researchers evaluated differences in treatment intensification and overall survival between patient groups.
Emily MenendezmCSPC | May 1, 2024
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
Katy MarshallmCSPC | April 17, 2024
Researchers performed a post hoc analysis on patient data from the randomized, phase 3 LATITUDE trial.
Emily MenendezmCSPC | March 26, 2024
A combination of androgen annihilation therapy with radiotherapy was tested for recurrent metastatic prostate cancer.
Katy MarshallmCSPC | March 13, 2024
Investigators evaluated the data of 427 patients with metastatic HSPC and serum initial PSA greater than 100 ng/ml.
Rahul Aggarwal, MDmCSPC | March 11, 2024
Dr. Aggarwal also discusses next steps regarding the intensification of ADT in patients with BRPC.
Emily MenendezmHSPC | February 28, 2024
Phase III mHSPC trials can take up to a decade to complete when OS is used as the primary endpoint.
Katy MarshallmCSPC | February 8, 2024
The addition of apalutamide to ADT should be considered in patients with high-risk BRPC, according to researchers.
Christopher Wallis, MD, PhD, FRCSCASCO GU Symposium 2024 | January 30, 2024
Dr. Wallis highlights his population-based research on treatment intensification shortcomings in de novo mCSPC.
Katy MarshallASCO GU Symposium 2024 | January 23, 2024
Researchers evaluated real-world survival for patients with mCSPC who received enzalutamide or apalutamide treatment.
Katy MarshallmCSPC | December 29, 2023
Researchers noted a lack of research surrounding treatment-related adverse events in these patients.
John Shen, MDmCSPC | December 19, 2023
Drs. Shen and Graff discuss patient outcomes from TITAN and SPARTAN, as well as assessing functional vs chronological age.
Emily MenendezCRPC | November 20, 2023
Compared with ADT alone, apalutamide plus ADT had a favorable hazard ratio across all end points regardless of age.
Vadim Koshkin, MDProstate Cancer | October 31, 2023
The trio highlights the results of a study on whether bone scans overstage PC compared with PSMA PET at initial staging.
Vadim Koshkin, MDProstate Cancer | October 31, 2023
A background on PSMA PET scans for staging of prostate cancer and comparison of accuracy of conventional vs PSMA PET imaging.
Zachary BessetteESMO 2023 | October 18, 2023
Research shed light on the safety and efficacy of pembrolizumab plus enzalutamide and ADT in patients with NHA-naïve mHSPC.